Antisense technology: A review

被引：151

作者：

Crooke, Stanley T. ^{[1
]}

Liang, Xue-Hai ^{[1
]}

Baker, Brenda F. ^{[2
]}

Crooke, Rosanne M. ^{[3
]}

机构：

[1] Ionis Pharmaceut Inc, Core Antisense Res, Carlsbad, CA 92008 USA

[2] Ionis Pharmaceut Inc, Dev Commun, Carlsbad, CA USA

[3] Ionis Pharmaceut Inc, Antisense Drug Discovery, Carlsbad, CA USA

来源：

JOURNAL OF BIOLOGICAL CHEMISTRY | 2021年 / 296卷

关键词：

HUMAN RNASE H1; DUCHENNE MUSCULAR-DYSTROPHY; RESISTANT PROSTATE-CANCER; I DOSE-ESCALATION; PHOSPHOROTHIOATE OLIGONUCLEOTIDES; MESSENGER-RNA; DOUBLE-BLIND; PHASE-I; TARGETING APOLIPOPROTEIN(A); HETERODUPLEX SUBSTRATE;

D O I：

10.1016/j.jbc.2021.100416

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Antisense technology is beginning to deliver on the broad promise of the technology. Ten RNA-targeted drugs including eight single-strand antisense drugs (ASOs) and two double-strand ASOs (siRNAs) have now been approved for commercial use, and the ASOs in phase 2/3 trials are innovative, delivered by multiple routes of administration and focused on both rare and common diseases. In fact, two ASOs are used in cardiovascular outcome studies and several others in very large trials. Interest in the technology continues to grow, and the field has been subject to a significant number of reviews. In this review, we focus on the molecular events that result in the effects observed and use recent clinical results involving several different ASOs to exemplify specific molecular mechanisms and specific issues. We conclude with the prospective on the technology.

引用

页数：39

共 230 条

[1] hnRNP A1 binds promiscuously to oligoribonucleotides: Utilization of random and homo-oligonucleotides to discriminate sequence from base-specific binding
AbdulManan, N
Williams, KR
[J]. NUCLEIC ACIDS RESEARCH, 1996, 24 (20) : 4063 - 4070
[2] Discovery of Innovative Small Molecule Therapeutics
Abou-Gharbia, Magid
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 2009, 52 (01) : 2 - 9
[3] Akcea Therapeutics Ionis Pharmaceuticals., 2020, AKC ION REP POS TOPL
[4] N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels
Alexander, Veronica J.
Xia, Shuting
Hurh, Eunju
Hughes, Steven G.
O'Dea, Louis
Geary, Richard S.
Witztum, Joseph L.
Tsimikas, Sotirios
[J]. EUROPEAN HEART JOURNAL, 2019, 40 (33) : 2785 - 2796
[5] Long-term treatment with eteplirsen in nonambulatory patients with Duchenne muscular dystrophy
Alfano, Lindsay N.
Charleston, Jay S.
Connolly, Anne M.
Cripe, Linda
Donoghue, Cas
Dracker, Robert
Dworzak, Johannes
Eliopoulos, Helen
Frank, Diane E.
Lewis, Sarah
Lucas, Karin
Lynch, Jessie
Milici, A. J.
Flynt, Amy
Naughton, Emily
Rodino-Klapac, Louise R.
Sahenk, Zarife
Schnell, Frederick J.
Young, G. David
Mendell, Jerry R.
Lowes, Linda P.
[J]. MEDICINE, 2019, 98 (26) : e15858
[6] Targeted delivery of antisense oligonucleotides to pancreatic β-cells
Ammala, C.
Drury, W. J., III
Knerr, L.
Ahlstedt, I
Stillemark-Billton, P.
Wennberg-Huldt, C.
Andersson, E-M
Valeur, E.
Jansson-Lofmark, R.
Janzen, D.
Sundstrom, L.
Meuller, J.
Claesson, J.
Andersson, P.
Johansson, C.
Lee, R. G.
Prakash, T. P.
Seth, P. P.
Monia, B. P.
Andersson, S.
[J]. SCIENCE ADVANCES, 2018, 4 (10):
[7] Entering the Modern Era of Gene Therapy
Anguela, Xavier M.
High, Katherine A.
[J]. ANNUAL REVIEW OF MEDICINE, VOL 70, 2019, 70 : 273 - 288
[8] Nucleic acid binding proteins affect the subcellular distribution of phosphorothioate antisense oligonucleotides
Bailey, Jeffrey K.
Shen, Wen
Liang, Xue-hai
Crooke, Stanley T.
[J]. NUCLEIC ACIDS RESEARCH, 2017, 45 (18) : 10649 - 10671
[9] EFFECT OF ION-PAIRING ON BOND ORDER AND CHARGE LOCALIZATION IN ALKYL PHOSPHOROTHIOATES
BARANIAK, J
FREY, PA
[J]. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1988, 110 (12) : 4059 - 4060
[10] Gene Expression Regulation by Upstream Open Reading Frames and Human Disease
Barbosa, Cristina
Peixeiro, Isabel
Romao, Luisa
[J]. PLOS GENETICS, 2013, 9 (08):

← 1 2 3 4 5 6 7 8 9 10 →